Short Interest in Knight Therapeutics Inc. (OTCMKTS:KHTRF) Expands By 14.4%

Knight Therapeutics Inc. (OTCMKTS:KHTRF) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 472,500 shares, a growth of 14.4% from the January 15th total of 413,200 shares. Based on an average trading volume of 1,400 shares, the days-to-cover ratio is currently 337.5 days.

Knight Therapeutics Price Performance

KHTRF traded up $0.09 on Monday, hitting $3.98. The company had a trading volume of 101 shares, compared to its average volume of 1,287. Knight Therapeutics has a 12-month low of $3.48 and a 12-month high of $4.55. The stock has a fifty day moving average price of $3.78 and a 200-day moving average price of $3.98.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.